The McArthur laboratory investigates oncogenes as therapeutic targets for cancer.
By targeting oncogenic signalling in cancer and understanding the impact of this therapy on both the tumour cell and its microenvironment, we aim to develop novel treatment strategies that are durable and prevent therapy resistance. The McArthur laboratory has a specific interest in melanoma, but also investigates pancreatic and oesophageal cancer.
Major themes include:
- Defining the molecular events underpinning targeted therapy response, tolerance and resistance.
- Role of cellular metabolism in the response to targeted and immune therapies
- Immunobiology of melanoma
- Translating our pre-clinical studies into clinical trials
Targeting CDK4 in melanoma
Melanoma treatment is undergoing a fundamental change due to the success of both BRAF targeted and immune therapies; however, both have their limitations. Typically, targeted therapies are associated with short-term responses due to acquisition of therapy resistance in patients; in contrast, immunotherapies have a lower patient response rate, but have long-term responses.
In preclinical studies using melanoma cell lines and in vivo models, we have demonstrated remarkably prolonged responses to a combination of targeted inhibitors to mutant BRAF and CDK4. We are now investigating how the combination of BRAF/MEK/ERK and CDK4 inhibitors induce durable responses. Furthermore, we are investigating the potential mechanism behind the development of resistance to each of these therapies. Understanding mechanisms of resistance is now an essential part of targeted therapy development, as it can provide both a biomarker for early detection of treatment failure and options for alternative subsequent treatments.
Targeting PRMT5 in CDK4 driven cancer
We have recently identified Protein Arginine Methyltransferase 5 (PRMT5) as a potential new target for CDK4 driven cancers including melanoma, pancreatic and oesophageal cancer. PRMT5 through methylation of histones and many other proteins regulates a diverse array of cellular functions and its activity is regulated by CDK4.
Our preclinical studies have identified novel PRMT5 inhibitor combinational therapies that are effective in pre-clinical CDK4 driven cancer models. Using both genomic and proteomic approaches we aim to identify potential downstream targets and pathways that are required for sensitivity to PRMT5 inhibitors and thus potential biomarkers of sensitivity and mechanisms of resistance to this class of inhibitor. In addition, a comparison across melanoma, pancreatic and oesophageal cancer cell lines will provide insight into common and likely fundamental mediators involved in PRMT5 signalling and also those that are unique to each cancer type.
Metabolic reprogramming in BRAF mutant melanoma
Metabolic reprogramming is a recognised hallmark of cancer. To support continued proliferation and growth, tumour cells must metabolically adapt to balance their bioenergetic and biosynthetic needs. To achieve this, cancer cells switch from mitochondrial oxidative phosphorylation to predominantly rely on glycolysis, a process known as the Warburg effect. The BRAF oncogene, mutated in approximately 50 per cent of melanoma patients, has recently emerged as a critical regulator of this process, bringing to the fore the importance of metabolic reprogramming in the pathogenesis and treatment of melanoma.
To further explore regulation of glycolysis by BRAF, we have performed a genome-wide RNAi screen. This approach has identified a network of novel protein complexes and pathways that may play a role in coupling oncogenic BRAF signalling to metabolic reprogramming. Significantly, depletion of components of this network specifically synergise with vemurafenib to potently suppress glycolysis and survival. These novel regulators of BRAF-driven metabolic reprogramming are under further investigation, using metabolomics and Seahorse Extracellular Flux analysis, for their potential as therapeutic targets in the context of BRAF-mutant melanoma.
Impact of targeted therapy on the tumour immune microenvironment
Melanoma is considered highly immunogenic but has evolved mechanisms that disable immune recognition and attack. Many small molecule inhibitors including BRAF, MEK and CDK4 inhibitors affect the tumour immune microenvironment, either promoting or diminishing the anti-tumour immune response. Understanding the impact of targeted therapy on both tumour immunogenicity and directly on immune cells is essential in advancing these agents, as well as their combination with immune therapies, into the clinic.
Using human melanoma cell lines, in vivo mouse models and patient samples, we are currently investigating the direct effect of targeted therapies on immune cell function and tumour immunogenicity. To do this we are using a variety of techniques including single cell RNA sequencing, flow cytometry and multiplex immunohistochemistry. In addition, we are assessing how these targeted therapies can be successfully combined with immune therapies to sustain tumour regression.
Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, Slater A, Lau P, Meeth K, Oliaro J, Haynes N, McArthur GA, Sheppard KE (2019). A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. Scientific Reports. 9(1):1225
Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE (2018). Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance. Int J Cancer.142(10):2139-2152.
Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol.19(5):672-681.
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, KE Sheppard, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA (2014). Response of BRAF mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 4(4):423-33.
Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, Pearson RB, Christensen JG, Randolph S, McArthur GA, Sheppard KE (2014). Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 27(4):590–600.
Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study.
Lancet Oncol. 15(9):954-65.
Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA (2013). BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Clin Cancer Res.19(17):4589-98.